Loading...
Loading...
MYOV| Name | Value |
|---|---|
| Revenues | 116.5M |
| Cost of Revenue | 22.9M |
| Gross Profit | 93.6M |
| Operating Expense | 102.9M |
| Operating I/L | -9.4M |
| Other Income/Expense | -3.7M |
| Interest Income | 0.5M |
| Pretax | -13.1M |
| Income Tax Expense | 8.2M |
| Net Income/Loss | -21.2M |
Myovant Sciences Ltd. is a biopharmaceutical company focused on developing innovative treatments for women's and men's health. The company's lead product, relugolix, is an oral, once-daily, small molecule used to treat heavy menstrual bleeding related to uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. Additionally, Myovant Sciences is developing MVT-602, a kisspeptin agonist, for the treatment of female infertility in assisted reproduction. The company has a collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health, driving its revenue through product development and commercialization.
